Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €168.38 EUR
Change Today +0.96 / 0.57%
Volume 19.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 9:35 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Open
€168.00
Previous Close
€167.42
Day High
€168.48
Day Low
€167.22
52 Week High
04/13/15 - €178.72
52 Week Low
06/18/14 - €62.62
Market Cap
7.8B
Average Volume 10 Days
5.6
EPS TTM
--
Shares Outstanding
46.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTH)

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

740 Employees
Last Reported Date: 02/24/15
Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Co-Chief Executive Offi...
Total Annual Compensation: $1.0M
Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: $840.4K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $731.0K
Compensation as of Fiscal Year 2014.

united therapeutics corp (UTH) Key Developments

United Therapeutics Corporation Adopts Amendment to the Third Amended and Restated By-Laws

On April 29, 2015, the Board of Directors of United Therapeutics Corporation adopted Amendment No. 1 to the company’s Third Amended and Restated By-Laws. The Amendment became effective immediately upon approval by the Board, and contains a new proxy access provision at Section 2.14, which permits a shareholder or group of up to 20 shareholders owning shares representing at least 3% of the outstanding voting stock of the Company entitled to vote in the election of directors continuously for at least 3 years to nominate and include in the Company’s proxy materials directors constituting up to 20% of the total number of directors then serving on the Board, except that the limit shall be 25% if fewer than 10 directors are then serving on the Board, provided that the shareholder(s) and nominee(s) satisfy the requirements specified in Section 2.14 of the By-laws. The Amendment also makes certain clarifications, updates and other non-substantive changes to the advance notice provisions of Section 2.5 of the By-laws.

United Therapeutics Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Effective Tax Guidance for the Year 2015

United Therapeutics Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's total revenues were $327,504,000 against $289,403,000 a year ago. Operating loss was $14,826,000 against income of $216,140,000 a year ago. Loss before income taxes was $16,792,000 against income of $213,216,000 a year ago. Net loss was $16,641,000 or $0.36 basic and diluted per share against income of $137,524,000 or $2.43 basic and diluted per share a year ago. Non-GAAP earnings were $134,964,000 or $2.55 diluted per share against $106,210,000 or $1.87 basic and diluted per share a year ago. The estimated annual effective tax rates were approximately 38% and approximately 35% as of March 31, 2015 and March 31, 2014, respectively. The company's 2015 estimated annual effective tax rate increased as of March 31, 2015, primarily due to an increase in the amount of non-deductible compensation expense during 2015, as compared to 2014.

United Therapeutics Corporation to Report Q1, 2015 Results on Apr 28, 2015

United Therapeutics Corporation announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on Apr 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €168.38 EUR +0.96

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.133.20 CHF -0.50
Alexion Pharmaceuticals Inc $166.19 USD -1.93
Celanese Corp $68.64 USD +0.35
Nippon Shinyaku Co Ltd ¥3,825 JPY 0.00
Vertex Pharmaceuticals Inc $127.40 USD -0.40
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 51.0x
Price/Sales 6.5x
Price/Book 7.8x
Price/Cash Flow 45.6x
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.